Entolimod - Cleveland BioLabs

Drug Profile

Entolimod - Cleveland BioLabs

Alternative Names: CBLB 502

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cleveland BioLabs
  • Class Anti-ischaemics; Antidotes; Antineoplastics; Chemoprotectants; Peptides; Radioprotectives
  • Mechanism of Action Apoptosis inhibitors; NF-kappa B modulators; Toll-like receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute radiation syndrome
  • Phase II Colorectal cancer
  • Phase I Cancer
  • Preclinical Radiation injuries
  • No development reported Reperfusion injury

Most Recent Events

  • 28 Mar 2018 Cleavland receives Day 120 review questions from the EMA for entolimod in Acute radiation syndrome
  • 15 Nov 2017 Preregistration for Acute radiation syndrome in European Union (IM)
  • 17 Apr 2017 EMA accepts Paediatric Investigation Plan (PIP) filed by Cleveland bioLabs as a medical radiation countermeasure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top